Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder clinical trials

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

This study looks at a new medicine called dexpramipexole for severe asthma. It wants to see if the medicine can reduce asthma flare-ups and improve breathing over 52 weeks. Researchers will compare it to a dummy medicine to see if it works and is safe.